Mankind Pharma reported a 30% rise in quarterly net profit to ₹568 crore for Q1 FY27, driven by strong domestic performance in chronic and cardiac segments. Revenue grew 13% to ₹4,031 crore, with improved operational efficiency boosting profit margins to 26.2%.
Mankind Pharma has reported strong financial results for the quarter ended June 30, 2026, marking a significant start to the new fiscal year. The company recorded a net profit of ₹568 crore, representing a 30% increase compared to the same period in the previous year. This growth was supported by a 13% rise in total revenue from operations, which reached ₹4,031 crore.
Operational Efficiency and Margin Gains
A key highlight of the recent performance is the improvement in operating profitability. The company reported an EBITDA of ₹1,057 crore, a 25% increase year-on-year. Consequently, the EBITDA margin expanded to 26.2%, up from 23.7% in the same quarter last year. This expansion suggests that the company is managing its costs more effectively even as it expands its product portfolio. Investors generally monitor such margin trends to assess a company’s ability to maintain profitability in a competitive pharmaceutical market.
Growth Across Key Segments
The domestic business remains the primary engine for Mankind Pharma. Excluding its consumer healthcare division, the company saw 11% growth in its domestic operations. The chronic portfolio, which includes treatments for long-term health conditions, emerged as a major contributor, growing by 15.8%. Within this portfolio, cardiac therapies performed particularly well with a 19.4% increase, while anti-diabetes treatments grew by 12.7%. The company also saw a recovery in its acute healthcare business, with growth in segments like gastrointestinal, vitamins, minerals, and nutrients (VMN), and gynaecology.
Consumer and Global Reach
Beyond its core domestic pharmaceuticals, Mankind Pharma’s consumer healthcare segment grew by 4%. The company noted that it gained market share in key consumer brands such as Manforce and Prega News. Additionally, the company is seeing a shift in sales channels, with modern trade and e-commerce platforms growing by 38%, now accounting for 15% of the company's total revenue. Internationally, the business continues to scale, posting a 29% revenue increase. The company has reached 49 products in the US market following the launch of a new product during this quarter.
Future Monitorables
Looking ahead, investors may track the company's ability to sustain its chronic therapy growth and maintain current margin levels. While the company is expanding its footprint in the US and strengthening its e-commerce presence, the integration of newer specialty business acquisitions and the competitive pressure in the domestic acute segment remain important areas for future assessment. The consistency of these margin gains against potential changes in raw material costs or pricing regulations will be key factors to follow in upcoming quarters.